Fundraising Fox
Nurix Therapeutics
San Francisco, US · Founded 2009 · 8 known investors
Find your way into Nurix Therapeutics
Sign up to see every warm intro you have to Nurix Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nurix Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
Founders & leadership
Board
Investors · 8
How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: generalatlantic.com · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · Not right? Tell us
How we know: The Column Group's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$139.4M disclosed across 3 rounds · 2013–2020
▶$120.2MraisedMar 2020 · 23 investors · OtherRule 506(b)
- Arthur SandsExecutive Officer, Director
- Lori KunkelDirector
- Julia GregoryDirector
- Jeff TongDirector
- Robert TjianDirector
- David LaceyDirector
- Christine RingExecutive Officer
- Hans van HouteExecutive Officer
- Leon ChenDirector
- Offering amount
- $120.2M
- Amount sold
- $120.2M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17MraisedSep 2015 · 1 investors · OtherRule 506(b)
- David GoeddelDirector
- Mark GoldsmithDirector
- Arthur T. SandsExecutive Officer, Director
- Timothy KutzkeyExecutive Officer, Director
- Offering amount
- $17M
- Amount sold
- $17M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedJan 2014 · 2 investors · OtherRule 506(b)
- Mark GoldsmithExecutive Officer, Director
- Timothy KutzkeyExecutive Officer, Director
- David GoeddelDirector
- Offering amount
- $25.1M
- Amount sold
- $2.1M
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Nurix Therapeutics do?
- Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
- Who are Nurix Therapeutics's investors?
- Nurix Therapeutics's investors include Bain Capital Life Sciences, EcoR1 Capital, Foresite Capital, General Atlantic, Sofinnova Ventures, The Column Group, Wellington Management, Third Rock Ventures.
- How much funding has Nurix Therapeutics raised?
- Nurix Therapeutics has disclosed $139.4M raised across 3 rounds.
- Where is Nurix Therapeutics headquartered?
- Nurix Therapeutics is headquartered in San Francisco, US.